Home ➤ Life Science ➤ Diagnostics ➤ Immune Checkpoint Inhibitors Market
Immune Checkpoint Inhibitors Market
Published date: Aug 2024 • Formats:
Request Sample Schedule a Call

Global Immune Checkpoint Inhibitors Market By Type (CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor) By Disease Indication (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, Others) By End-User (Hospitals, Specialty Clinics, Academic & Research Institutions) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • Published date: Aug 2024
  • Report ID: 127673
  • Number of Pages: 293
  • Format:
  • keyboard_arrow_up

  • Table of Contents

    1. Executive Summary

    • 1.1. Definition
    • 1.2. Market Snapshot
    • 1.3. Market Overview
    • 1.4. Segment Overview
    • 1.5. Regional Overview
    • 1.6. Competitive Landscape
    • 1.7. Taxonomy

    2. Global Market Overview

    • 2.1. Global Market Insights and Industry Overview
    • 2.2. Market Dynamics
      • 2.2.1. Drivers
      • 2.2.2. Restraints
      • 2.2.3. Opportunities
      • 2.2.4. Key Immune Checkpoint Inhibitors Market Trends
    • 2.3. Regulatory Framework
    • 2.4. Opportunity Map Analysis
    • 2.5. Opportunity Orbits
    • 2.6. PESTLE Analysis
    • 2.7. PORTER’S Five Force Analysis
    • 2.8. Drivers & Restraints Impact Analysis
    • 2.9. Value Chain Analysis
      • 2.9.1. List of Raw Materials Suppliers
      • 2.9.2. List of Immune Checkpoint Inhibitors Manufacturers
      • 2.9.3. List of Dealer/Distributors
    • 2.10. Regional Market Share and BPS Analysis
    • 2.11. Impact of Macro-economic Factors/Geopolitical Factors

    3. Global Immune Checkpoint Inhibitors Market Analysis and Forecast, By Segment, 2018-2032

    • 3.1. Key Findings
    • 3.2. Global Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Type, 2018-2032
    • 3.3. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
      • 3.3.1. CTLA-4 inhibitor
        • 3.3.1.1. Insights
        • 3.3.1.2. Key Takeaways
      • 3.3.2. PD-1 inhibitor
        • 3.3.2.1. Insights
        • 3.3.2.2. Key Takeaways
      • 3.3.3. PD-L1 inhibitor
        • 3.3.3.1. Insights
        • 3.3.3.2. Key Takeaways
    • 3.4. Global Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Indication, 2018-2032
    • 3.5. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
      • 3.5.1. Lung Cancer
        • 3.5.1.1. Insights
        • 3.5.1.2. Key Takeaways
      • 3.5.2. Bladder Cancer
        • 3.5.2.1. Insights
        • 3.5.2.2. Key Takeaways
      • 3.5.3. Melanoma
        • 3.5.3.1. Insights
        • 3.5.3.2. Key Takeaways
      • 3.5.4. Colorectal Cancer
        • 3.5.4.1. Insights
        • 3.5.4.2. Key Takeaways
      • 3.5.5. Hodgkin lymphoma
        • 3.5.5.1. Insights
        • 3.5.5.2. Key Takeaways
      • 3.5.6. Others
        • 3.5.6.1. Insights
        • 3.5.6.2. Key Takeaways
    • 3.6. Global Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2018-2032
    • 3.7. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
      • 3.7.1. Hospitals
        • 3.7.1.1. Insights
        • 3.7.1.2. Key Takeaways
      • 3.7.2. Specialty Clinics
        • 3.7.2.1. Insights
        • 3.7.2.2. Key Takeaways
      • 3.7.3. Academic & Research Institutions
        • 3.7.3.1. Insights
        • 3.7.3.2. Key Takeaways

    4. Global Immune Checkpoint Inhibitors Market Analysis and Forecast, By Region, 2018-2032

    • 4.1. Key Findings
    • 4.2. Global Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2018-2032
      • 4.2.1. North America
        • 4.2.1.1. Regional Insights
      • 4.2.2. Europe
        • 4.2.2.1. Regional Insights
      • 4.2.3. Asia Pacific
        • 4.2.3.1. Regional Insights
      • 4.2.4. Latin America
        • 4.2.4.1. Regional Insights
      • 4.2.5. Middle East & Africa
        • 4.2.5.1. Regional Insights
    • 4.3. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Region

    5. North America Immune Checkpoint Inhibitors Market Analysis and Forecast, 2018-2032

    • 5.1. Key Findings
    • 5.2. North America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Type, 2018-2032
    • 5.3. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • 5.4. North America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Indication, 2018-2032
    • 5.5. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • 5.6. North America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2018-2032
    • 5.7. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • 5.8. North America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2018-2032
    • 5.9. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
      • 5.9.1. The US
      • 5.9.2. Canada

    6. Europe Immune Checkpoint Inhibitors Market Analysis and Forecast, 2018-2032

    • 6.1. Key Findings
    • 6.2. Europe Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Type, 2018-2032
    • 6.3. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • 6.4. Europe Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Indication, 2018-2032
    • 6.5. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • 6.6. Europe Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2018-2032
    • 6.7. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • 6.8. Europe Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2018-2032
    • 6.9. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
      • 6.9.1. Germany
      • 6.9.2. The UK
      • 6.9.3. France
      • 6.9.4. Spain
      • 6.9.5. Italy
      • 6.9.6. Russia
      • 6.9.7. Netherlands
      • 6.9.8. Rest of Europe

    7. Asia Pacific Immune Checkpoint Inhibitors Market Analysis and Forecast, 2018-2032

    • 7.1. Key Findings
    • 7.2. Asia Pacific Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Type, 2018-2032
    • 7.3. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • 7.4. Asia Pacific Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Indication, 2018-2032
    • 7.5. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • 7.6. Asia Pacific Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2018-2032
    • 7.7. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • 7.8. Asia Pacific Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2018-2032
    • 7.9. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
    • 7.9.1. China
    • 7.9.2. Japan
    • 7.9.3. South Korea
    • 7.9.4. India
    • 7.9.5. New Zealand
    • 7.9.6. Singapore
    • 7.9.7. Thailand
    • 7.9.8. Vietnam
    • 7.9.9. Rest of Asia Pacific

    8. Latin America Immune Checkpoint Inhibitors Market Analysis and Forecast, 2018-2032

    • 8.1. Key Findings
    • 8.2. Latin America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Type, 2018-2032
    • 8.3. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • 8.4. Latin America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Indication, 2018-2032
    • 8.5. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • 8.6. Latin America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2018-2032
    • 8.7. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • 8.8. Latin America Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2018-2032
    • 8.9. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
      • 8.9.1. Brazil
      • 8.9.2. Mexico
      • 8.9.3. Rest of Latin America

    9. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis and Forecast, 2018-2032

    • 9.1. Key Findings
    • 9.2. Middle East & Africa Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Type, 2018-2032
    • 9.3. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • 9.4. Middle East & Africa Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Disease Indication, 2018-2032
    • 9.5. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • 9.6. Middle East & Africa Immune Checkpoint Inhibitors Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2018-2032
    • 9.7. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
      • 9.7.1. South Africa
      • 9.7.2. Saudi Arabia
      • 9.7.3. UAE
      • 9.7.4. Rest of Middle East & Africa

    10. Competitive Landscape & Company Profiles

    • 10.1. Market Competition Scenario Analysis, By Company
      • 10.1.1. Key Takeaways
    • 10.2. Overview of Major Market Players
    • 10.3. Competitor Landscape
    • 10.4. Strategic Mapping
    • 10.5. Company Life Cycle Analysis
    • 10.6. Company Market Share Analysis
    • 10.7. Company Profiles
      • 10.7.1. AstraZeneca plc
        • 10.7.1.1. Company Details
        • 10.7.1.2. Business Overview
        • 10.7.1.3. Product Portfolio
        • 10.7.1.4. Financial Insights
        • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.1.6. SWOT Analysis
        • 10.7.1.7. Geographic Footprint
      • 10.7.2. F. Hoffmann-La Roche Ltd.
        • 10.7.2.1. Company Details
        • 10.7.2.2. Business Overview
        • 10.7.2.3. Product Portfolio
        • 10.7.2.4. Financial Insights
        • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.2.6. SWOT Analysis
        • 10.7.2.7. Geographic Footprint
      • 10.7.3. Merck KGaA
        • 10.7.3.1. Company Details
        • 10.7.3.2. Business Overview
        • 10.7.3.3. Product Portfolio
        • 10.7.3.4. Financial Insights
        • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.3.6. SWOT Analysis
        • 10.7.3.7. Geographic Footprint
      • 10.7.4. Regeneron Pharmaceuticals, Inc.
        • 10.7.4.1. Company Details
        • 10.7.4.2. Business Overview
        • 10.7.4.3. Product Portfolio
        • 10.7.4.4. Financial Insights
        • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.4.6. SWOT Analysis
        • 10.7.4.7. Geographic Footprint
      • 10.7.5. Bristol-Myers Squibb Company
        • 10.7.5.1. Company Details
        • 10.7.5.2. Business Overview
        • 10.7.5.3. Product Portfolio
        • 10.7.5.4. Financial Insights
        • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.5.6. SWOT Analysis
        • 10.7.5.7. Geographic Footprint
      • 10.7.6. Innovent Biologics, Inc.
        • 10.7.6.1. Company Details
        • 10.7.6.2. Business Overview
        • 10.7.6.3. Product Portfolio
        • 10.7.6.4. Financial Insights
        • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.6.6. SWOT Analysis
        • 10.7.6.7. Geographic Footprint
      • 10.7.7. BeiGene, Ltd.
        • 10.7.7.1. Company Details
        • 10.7.7.2. Business Overview
        • 10.7.7.3. Product Portfolio
        • 10.7.7.4. Financial Insights
        • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.7.6. SWOT Analysis
        • 10.7.7.7. Geographic Footprint
      • 10.7.8. Shanghai Junshi Biosciences Co., Ltd.
        • 10.7.8.1. Company Details
        • 10.7.8.2. Business Overview
        • 10.7.8.3. Product Portfolio
        • 10.7.8.4. Financial Insights
        • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.8.6. SWOT Analysis
        • 10.7.8.7. Geographic Footprint
      • 10.7.9. GlaxoSmithKline plc
        • 10.7.9.1. Company Details
        • 10.7.9.2. Business Overview
        • 10.7.9.3. Product Portfolio
        • 10.7.9.4. Financial Insights
        • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
        • 10.7.9.6. SWOT Analysis
        • 10.7.9.7. Geographic Footprint
        • 10.7.10. Other Key Players

    11. Methodology and Data Source

      • 11.1. Methodology/Research Approach
      • 11.2. Market Size Estimation
      • 11.3. Market Breakdown and Data Triangulation
      • 11.4. Data Source
      • 11.5. Secondary Sources
      • 11.6. Primary Sources
      • 11.7. Appendix
      • 11.8. Disclaimer

    List of Tables

    • Table 1. Global Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 2. Global Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 3. Global Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 4. Global Immune Checkpoint Inhibitors Market Value (US$ Mn), By Region, 2018-2032
    • Table 5. North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 6. North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 7. North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 8. North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country, 2018-2032
    • Table 9. The US Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 10. The US Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 11. The US Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 12. Canada Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 13. Canada Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 14. Canada Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 15. Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 16. Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 17. Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 18. Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country, 2018-2032
    • Table 19. Germany Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 20. Germany Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 21. Germany Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 22. The UK Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 23. The UK Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 24. The UK Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 25. France Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 26. France Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 27. France Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 28. Spain Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 29. Spain Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 30. Spain Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 31. Italy Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 32. Italy Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 33. Italy Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 34. Russia Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 35. Russia Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 36. Russia Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 37. Netherlands Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 38. Netherlands Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 39. Netherlands Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 40. Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 41. Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 42. Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 43. Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel, 2018-2032
    • Table 44. Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 45. Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 46. Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 47. Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 48. Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country, 2018-2032
    • Table 49. China Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 50. China Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 51. China Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 52. India Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 53. India Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 54. India Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 55. Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 56. Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 57. South Korea Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 58. South Korea Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 59. South Korea Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 60. New Zealand Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 61. New Zealand Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 62. New Zealand Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 63. Singapore Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 64. Singapore Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 65. Singapore Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 66. Singapore Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel, 2018-2032
    • Table 67. Singapore Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 68. Thailand Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 69. Thailand Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 70. Thailand Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 71. Vietnam Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 72. Vietnam Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 73. Vietnam Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 74. Rest of Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 75. Rest of Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 76. Rest of Asia Pacific Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 77. Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 78. Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 79. Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 80. Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country, 2018-2032
    • Table 81. Brazil Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 82. Brazil Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 83. Brazil Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 84. Mexico Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 85. Mexico Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 86. Mexico Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 87. Rest of Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 88. Rest of Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 89. Rest of Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 90. Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 91. Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 92. Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 93. Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country, 2018-2032
    • Table 94. South Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 95. South Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 96. South Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 97. Saudi Arabia Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 98. Saudi Arabia Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 99. Saudi Arabia Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 100. UAE Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 101. UAE Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 102. UAE Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032
    • Table 103. Rest of Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Type, 2018-2032
    • Table 104. Rest of Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By Disease Indication, 2018-2032
    • Table 105. Rest of Middle East & Africa Immune Checkpoint Inhibitors Market Value (US$ Mn), By End-User, 2018-2032

    List of Figures

    • Figure 1. Global Immune Checkpoint Inhibitors Market Snapshot: Market Value (US$ Mn), 2019-2033
    • Figure 2. Opportunity Map
    • Figure 3. Opportunity Orbit
    • Figure 4. Regional Market Share and BPS Analysis in Immune Checkpoint Inhibitors Market
    • Figure 5. Global Immune Checkpoint Inhibitors Market Analysis, By Type, 2019, 2023 and 2033
    • Figure 6. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • Figure 7. Global Immune Checkpoint Inhibitors Market Analysis, By Disease Indication, 2019, 2023 and 2033
    • Figure 8. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • Figure 9. Global Immune Checkpoint Inhibitors Market Analysis, By End-User, 2019, 2023 and 2033
    • Figure 10. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • Figure 11. Global Immune Checkpoint Inhibitors Market Analysis, By Region, 2019, 2023 and 2034
    • Figure 12. Global Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Region
    • Figure 13. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • Figure 14. North America Immune Checkpoint Inhibitors Market (US$ Mn), by CTLA-4 inhibitor, 2019-2033
    • Figure 15. North America Immune Checkpoint Inhibitors Market (US$ Mn), by PD-1 inhibitor, 2019-2033
    • Figure 16. North America Immune Checkpoint Inhibitors Market (US$ Mn), by PD-L1 inhibitor, 2019-2033
    • Figure 17. North America Immune Checkpoint Inhibitors Market Analysis, By Disease Indication, 2019, 2023 and 2033
    • Figure 18. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • Figure 19. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Lung Cancer, 2019-2033
    • Figure 20. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Bladder Cancer, 2019-2033
    • Figure 21. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Melanoma, 2019-2033
    • Figure 22. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Colorectal Cancer, 2019-2033
    • Figure 23. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Hodgkin lymphoma, 2019-2033
    • Figure 24. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Others, 2019-2033
    • Figure 25. North America Immune Checkpoint Inhibitors Market Analysis, By End-User, 2019, 2023 and 2033
    • Figure 26. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • Figure 27. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Hospitals, 2019-2033
    • Figure 28. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Specialty Clinics, 2019-2033
    • Figure 29. North America Immune Checkpoint Inhibitors Market (US$ Mn), by Academic & Research Institutions, 2019-2033
    • Figure 30. North America Immune Checkpoint Inhibitors Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 31. North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
    • Figure 32. Europe Immune Checkpoint Inhibitors Market Analysis, By Type, 2019, 2023 and 2033
    • Figure 33. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • Figure 34. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by CTLA-4 inhibitor, 2019-2033
    • Figure 35. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by PD-1 inhibitor, 2019-2033
    • Figure 36. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by PD-L1 inhibitor, 2019-2033
    • Figure 37. Europe Immune Checkpoint Inhibitors Market Analysis, By Disease Indication, 2019, 2023 and 2033
    • Figure 38. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • Figure 39. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Lung Cancer, 2019-2033
    • Figure 40. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Bladder Cancer, 2019-2033
    • Figure 41. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Melanoma, 2019-2033
    • Figure 42. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Colorectal Cancer, 2019-2033
    • Figure 43. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Hodgkin lymphoma, 2019-2033
    • Figure 44. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Others, 2019-2033
    • Figure 45. Europe Immune Checkpoint Inhibitors Market Analysis, By End-User, 2019, 2023 and 2033
    • Figure 46. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • Figure 47. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Hospitals, 2019-2033
    • Figure 48. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Specialty Clinics, 2019-2033
    • Figure 49. Europe Immune Checkpoint Inhibitors Market (US$ Mn), by Academic & Research Institutions, 2019-2033
    • Figure 50. Europe Immune Checkpoint Inhibitors Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 51. Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
    • Figure 52. Asia Pacific Immune Checkpoint Inhibitors Market Analysis, By Type, 2019, 2023 and 2033
    • Figure 53. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • Figure 54. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by CTLA-4 inhibitor, 2019-2033
    • Figure 55. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by PD-1 inhibitor, 2019-2033
    • Figure 56. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by PD-L1 inhibitor, 2019-2033
    • Figure 57. Asia Pacific Immune Checkpoint Inhibitors Market Analysis, By Disease Indication, 2019, 2023 and 2033
    • Figure 58. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • Figure 59. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Lung Cancer, 2019-2033
    • Figure 60. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Bladder Cancer, 2019-2033
    • Figure 61. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Melanoma, 2019-2033
    • Figure 62. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Colorectal Cancer, 2019-2033
    • Figure 63. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Hodgkin lymphoma, 2019-2033
    • Figure 64. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Others, 2019-2033
    • Figure 65. Asia Pacific Immune Checkpoint Inhibitors Market Analysis, By End-User, 2019, 2023 and 2033
    • Figure 66. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • Figure 67. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Hospitals, 2019-2033
    • Figure 68. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Specialty Clinics, 2019-2033
    • Figure 69. Asia Pacific Immune Checkpoint Inhibitors Market (US$ Mn), by Academic & Research Institutions, 2019-2033
    • Figure 70. Asia Pacific Immune Checkpoint Inhibitors Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 71. Asia Pacific Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
    • Figure 72. Latin America Immune Checkpoint Inhibitors Market Analysis, By Type, 2019, 2023 and 2033
    • Figure 73. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • Figure 74. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by CTLA-4 inhibitor, 2019-2033
    • Figure 75. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by PD-1 inhibitor, 2019-2033
    • Figure 76. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by PD-L1 inhibitor, 2019-2033
    • Figure 77. Latin America Immune Checkpoint Inhibitors Market Analysis, By Disease Indication, 2019, 2023 and 2033
    • Figure 78. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • Figure 79. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Lung Cancer, 2019-2033
    • Figure 80. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Bladder Cancer, 2019-2033
    • Figure 81. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Melanoma, 2019-2033
    • Figure 82. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Colorectal Cancer, 2019-2033
    • Figure 83. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Hodgkin lymphoma, 2019-2033
    • Figure 84. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Others, 2019-2033
    • Figure 85. Latin America Immune Checkpoint Inhibitors Market Analysis, By End-User, 2019, 2023 and 2033
    • Figure 86. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • Figure 87. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Hospitals, 2019-2033
    • Figure 88. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Specialty Clinics, 2019-2033
    • Figure 89. Latin America Immune Checkpoint Inhibitors Market (US$ Mn), by Academic & Research Institutions, 2019-2033
    • Figure 90. Latin America Immune Checkpoint Inhibitors Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 91. Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
    • Figure 92. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis, By Type, 2019, 2023 and 2033
    • Figure 93. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Type
    • Figure 94. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by CTLA-4 inhibitor, 2019-2033
    • Figure 95. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by PD-1 inhibitor, 2019-2033
    • Figure 96. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by PD-L1 inhibitor, 2019-2033
    • Figure 97. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis, By Disease Indication, 2019, 2023 and 2033
    • Figure 98. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Disease Indication
    • Figure 99. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Lung Cancer, 2019-2033
    • Figure 100. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Bladder Cancer, 2019-2033
    • Figure 101. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Melanoma, 2019-2033
    • Figure 102. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Colorectal Cancer, 2019-2033
    • Figure 103. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Hodgkin lymphoma, 2019-2033
    • Figure 104. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Others, 2019-2033
    • Figure 105. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis, By End-User, 2019, 2023 and 2033
    • Figure 106. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By End-User
    • Figure 107. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Hospitals, 2019-2033
    • Figure 108. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Specialty Clinics, 2019-2033
    • Figure 109. Middle East & Africa Immune Checkpoint Inhibitors Market (US$ Mn), by Academic & Research Institutions, 2019-2033
    • Figure 110. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis, By Country, 2019, 2023 and 2033
    • Figure 111. Middle East & Africa Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Immune Checkpoint Inhibitors Market
  • 127673
  • Aug 2024
    • ★★★★★
      ★★★★★
    • (91)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options